Navigation Links
AUA releases new guidelines on non-muscle invasive bladder cancer
Date:11/9/2007

LINTHICUM, MD. The AUA is pleased to announce their new Guideline on the Management of Nonmuscle Invasive Bladder Cancer. Each year, more than 60,000 people are diagnosed with bladder cancer, which has been linked to a number of risk factors, including cigarette smoking and exposure to hazardous chemicals. The AUA originally published its guideline in 1999 and the report issued today is an update to that document.

The Guideline focuses on current treatment impacts on outcomes of interest to the patient, such as efficacy outcomes and occurrence of complications and side effects in treated patients. Unfortunately, new evidence on treatment modalities is scant and advances in treatment and physician education regarding treatment are limited.

The Guideline reviews a number of current treatments, including transurethral resection of bladder tumors (TURBT) and the use of chemotherapeutic agents (such as mitomycin C) and immunotherapeutic agents (such as bacillus Calmette-Guerin) in conjunction with TURBT. The panel also reviewed the efficacy of chemotherapy vs. immunotherapy in treating these non-invasive tumors, and the use of these agents in single induction courses compared to use as maintenance therapies.

The Guideline comes to the following conclusions based on current literature:

  • Accurate clinical staging upon which to base treatment decisions is critically important. The panel recommends performing a repeat TURBT prior to intravesical therapy in situations where there is high grade T1 disease without muscularis propria in the specimen and in select cases even when there is muscle present.

  • A single, post-operative instillation of a chemotherapeutic agent may decrease recurrence risk in patients with superficial disease who have undergone uncomplicated resection of the tumor(s).

  • There is no clear superiority of immunotherapy over chemotherapy for low risk disease. Induction courses of either intravesical chemotherapy or immunotherapy (BCG) should be administered in patients with an increased risk of tumor recurrence but low risk of progression.

  • An induction course of mitomycin C in conjunction with maintenance therapy enhances the effectiveness of the drug in preventing recurrence, however, no determinations have been made in regard to optimal maintenance dose, schedule or duration.

  • An induction course of BCG in conjunction with maintenance BCG therapy decreases recurrence and possibly progression in patients with higher risk tumors. Though no determinations on optimal schedule and duration have been made, data is available that supports the SWOG regimen.

Treatment algorithms are available both in the full document and the Executive Summary. However, many accepted studies used to develop these algorithms did not provide stratified outcomes data, and little data were available in regard to progression and survival. As a result, the panel felt the paucity of data needs to be addressed and corrected; the Guideline includes a discussion of future research needs and the optimal reporting of bladder cancer data. Most available studies focus primarily on recurrence and less on progression to muscle invasion a more important outcome with lethal implications.

Bladder cancer affects thousands of people each year and as the incidence of the disease rises, it is increasingly important that clinicians better understand how this disease progresses and how to stop it, said Craig Hall, M.D., chair of the panel that developed the Guideline. We may know more than ever about the diseases clinical behavior and molecular biology, but we need a larger body of strong research in order to educate physicians and make treatment recommendations.


'/>"/>

Contact: Wendy Isett
wisett@auanet.org
410-689-3789
American Urological Association
Source:Eurekalert

Related medicine news :

1. Cleveland Clinic Press Releases Journal-Writing Book Write for Life: Healing Body, Mind, and Spirit Through Journal Writing by Sheppard B. Kominars, Ph.D.
2. Leading Child Abuse Center Releases Back to School Tips to Protect Children From Internet Predators
3. JHA Releases 2007 U.S. Group Disability Mid-Year Market Survey Results
4. Verdict One Releases Directory of Board Certified Attorneys for Consumers
5. Academy releases emergency preparedness tools to enable millions more people to shelter in place
6. Provectus Pharmaceuticals, Inc. releases summary results of phase 1 metastatic melanoma study
7. MITEM Releases Blue Iris eLaborate 8.6
8. Produce for Better Health Foundation Releases Statement on Study Saying Fruit & Vegetable Consumption Not Strongly Associated With Colon Cancer Risk
9. Patient Safety Authority Releases Advisory Focusing on Common Causes of Medication Errors
10. URAC Releases Issue Briefs Examining Stakeholders Views of Care Coordination Along the Healthcare Continuum
11. Cardiac Science Releases New Cardiac Rehabilitation System
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... ... June 24, 2016 , ... The ... in Dallas that it will receive two significant new grants to support its ... PHA marked its 25th anniversary by recognizing patients, medical professionals and scientists for ...
(Date:6/24/2016)... CA (PRWEB) , ... June 24, 2016 , ... ... is now offering micro-osteoperforation for accelerated orthodontic treatment. Dr. Cheng has extensive experience ... Damon brackets , AcceleDent, and accelerated osteogenic orthodontics. , Micro-osteoperforation is ...
(Date:6/24/2016)... ... 2016 , ... Topical BioMedics, Inc, makers of Topricin and MyPainAway Pain Relief Products, join The ... raise to $12 an hour by 2020 and then adjusting it yearly to increase at ... the minimum wage, assure the wage floor does not erode again, and make future increases ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... ... today at the Clinical Decision Making in Emergency Medicine conference in Ponte Vedra ... authored journal articles published in Emergency Medicine Practice and Pediatric Emergency ...
(Date:6/24/2016)... ... June 24, 2016 , ... Puradigm® & Innovative Solutions today ... cultivation and processing operations at its production facility, and opened its first two ... the manufacturer of a complete system of proactive air and surface purification solutions ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... , June 24, 2016 ... appointment of Dr. Edward Futcher to ... Director, effective June 23, 2016.Dr. Futcher was also ... and Governance Committees.  As a non-executive member of ... expertise and strategic counsel to VolitionRx in connection ...
(Date:6/23/2016)... Calif. , June 23, 2016 Any dentist ... many challenges of the current process. Many of them do ... of the technical difficulties and high laboratory costs involved. And ... to offer it at such a high cost that the ... it. Dr. Parsa Zadeh , founder of ...
(Date:6/23/2016)... 2016 Research and Markets has announced ... Analysis 2016 - Forecast to 2022" report to their ... contains up to date financial data derived from varied research ... trends with potential impact on the market during the next ... which comprises of sub markets, regional and country level analysis. ...
Breaking Medicine Technology: